Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Advanced Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Large-scale testing (Phase 3)Study completedNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 281
Not applicableUnknownNCT05047848
What this trial is testing

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Liaoning Cancer Hospital & Institute 82
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05986071
What this trial is testing

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 57
Testing effectiveness (Phase 2)Looking for participantsNCT05594095
What this trial is testing

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Who this might be right for
Breast NeoplasmBreast CancerHormone Receptor Positive Tumor+2 more
Fudan University 620
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT03481998
What this trial is testing

SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Jiangsu HengRui Medicine Co., Ltd. 104
Testing effectiveness (Phase 2)UnknownNCT05806671
What this trial is testing

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06201234
What this trial is testing

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast CancerAdvanced or Metastatic Breast CancerBRCA1 Mutation+1 more
GBG Forschungs GmbH 176
Not applicableApproved For MarketingNCT02792725
What this trial is testing

Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)UnknownNCT04999540
What this trial is testing

Tucidinostat and Fulvestrant in Hormone-receptor Positive Advanced Breast Cancer

Who this might be right for
Breast Cancer
Guangdong Women and Children Hospital 73
Not applicableStudy completedNCT01171417
What this trial is testing

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

Who this might be right for
PostmenopauseBreast Cancer
AstraZeneca 570
Not applicableNo Longer AvailableNCT05108740
What this trial is testing

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

Who this might be right for
Advanced Hormone Receptor Positive (HR+) Breast Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Active Not RecruitingNCT03393845
What this trial is testing

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Nancy Chan, MD 47
Early research (Phase 1)Ended earlyNCT07121244
What this trial is testing

68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Who this might be right for
Locoregionally Recurrent Hormone-receptor Positive Breast CancerMetastatic Hormone Receptor Positive Breast Cancer
Radionetics Oncology 11
Testing effectiveness (Phase 2)Looking for participantsNCT07610720
What this trial is testing

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Who this might be right for
Advanced/Metastatic Breast CancerHER2-Positive Metastatic Breast Cancer
Sun Yat-sen University 57
Large-scale testing (Phase 3)Not Yet RecruitingNCT07061717
What this trial is testing

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

Who this might be right for
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 474
Not applicableStudy completedNCT02023359
What this trial is testing

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Healthcare A/S 7
Not applicableUnknownNCT03768479
What this trial is testing

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerFulvestrant
First Affiliated Hospital Xi'an Jiaotong University 68
Testing effectiveness (Phase 2)Looking for participantsNCT07330544
What this trial is testing

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Who this might be right for
Breast Cancer
Zhejiang Cancer Hospital 118
Next Page